KAKKIS EMIL D (President & CEO) sold 0.5% of their position (11.73K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $495.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/31/2024ACC: 0000950170-24-141485
DirectorOfficer· President & CEO
Since Mar 2026
-11.73K
Net shares
Net seller
$495.2K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
11.73K disposed
Non-Derivative Transactions1
Common Stock
Indirect
Shares
−11.73K
Price / share
$42.23
Trade value
$495.23K
% of position
0.5%
12/30/2024
2.20M→2.18M
Total
Net shares
−11.73K
Net value
-$495.23K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 12/30/2024 | S · Sale | −11.73K | $42.23 | $495.23K | 0.5% | 2.20M | 2.18M |
| Total | −11.73K | -$495.23K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned564.61K
Total
564.61K direct564.61K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 564.61K | Direct |
| Total | 564.61K | 564.61K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported